BIO-MATRIX SCIENTIFIC GROUP, INC. - A Stem Cell Company
(A Subsidiary of Tasco Holdings International, Inc. - OTCBB: THII)
Princeton Research July 14, 2006
Volume I, Issue 2
Current Price: $2.80
Target Price: $7.70
• As of June 14, 2006, all members of
the Tasco Holdings International
board resigned and elected Dr. David
R. Koos and Mr. Brian Pockett as incoming
Directors of Tasco Holdings
• Shareholders of BMXP to receive a
• Company Name change of the Tasco
Holdings International, Inc. and THII
symbol to agreement with Bio-Matrix
Scientific Group is pending.
In STEM CELL
SOLUTIONS For STEM
Bio-Matrix Scientific Group Inc. (OTC BB:
THII) is aligning itself with partners that offer
support of key technologies in medical applications.
This new placement after reversemerging
into Tasco Holdings International,
Inc. will help them achieve the financing for
those projects which they have focused on the
best: invention and securing intellectual property
rights to the medical processes and devices
that are critical to the biomedical device
development, tissue engineering, cell culturing,
genome therapy and drug delivery systems.
Originally they were dedicated to the research
and development of disposable devices and
instruments critical to the stem cell research
and tissue transfer medical applications. During
that time they have developed 192 different
instruments for service in the plastic surgery,
stem cell and tissue management fields.
The Bio-Matrix link to plastic surgery has
helped launch their next step. They have
constructed new labs and a cryogenic storage
facility for patients wishing to preserve their
own stem cells, taken from adipose (fat tissue)
extracted from a patient during the liposuction
process. In the event the patient requires
stem cell therapy for treatment of a
future health problem, these stem cells may
then be taken from the adipose tissue that has
been cryo-preserved. This process of using
adipose tissue derived stem cell previously
cryo-preserved provides several benefits for
the patient, above all reducing the risk of cell
tissue rejection by eliminating donor issues.
Likewise, the facility may be used to store a
newborn “cord blood” stem cells for possible
therapies that might be required later in life.
Stem cell therapies are now being seen to
assist in the treatment of several diseases
associated with aging, such as Parkinson’s
and Alzheimer’s Disease. With the emphasis
on continuing research and development, Bio-
Matrix Scientific Group may well be a mainstay
contributor to the future’s innovative
therapies. They continue to seek improvement
and ways to develop more instruments
and products to suit the demands of plastic
surgery, stem cell and tissue research. The
goal of their organization mission is to ultimately
enhance the quality of life.
Lab technician preparing cell culture
“ This is a $7 to $8 stock. With less than 13 million shares outstanding,
THII deserves capitalization of 75-85 million dollars. Bio-
Matrix has made incredible strides some of the most exciting and innovative
concepts in biotechnology. The process of removing unwanted
tissue (fat) and saving it for its stem cell use in the possibility of future
need is a breakthrough step. This will continue to prove itself to be
an incredible investment opportunity. ”
Mike King, Director of Princeton Research, Inc.
Liquid Nitrogen Storage
Clean Room Piping
Page 2 Bio-Matrix Scientific Group July 14, 2006
Bio-Matrix Scientific Group’s
Plastic Surgery Connection
The American Society of Plastic Surgeons records on the
most popular Cosmetic Surgery Procedures shows that in
the last 5 years, Liposuction has risen to become the most
common. The number of surgeries comprising the top 5
has diminished by 10% in five years, but in part due to new
processes that are substituting as intermediary treatments.
For example, facelifts are now off of the top 5 because of
the advent of collagen and botox injections as a less invasive
means of achieving a similar appearance result.
For all of the top procedures, Bio-Matrix Scientific
Group’s surgical instrument kits have been developed for
providing direct assistance to the surgeon. They additionally
have six provisional patent applications, a utility patent
application, and an international patent application for proprietary
devices developed exclusively for cell harvesting
and tissue transfer procedures.
Statistics from 2000
The term "forward-looking statements" is defined
in Section 27A of the Securities Act of 1933 as
amended (the “Securities Act”), and Section 21E of
the Securities Exchange Act of 1934 as amended the
“Exchange Act.” This article’s statements, with the
exception of historical fact statements, are reasonable;
the company, however, can give no assurance
that such expectations will prove different. This
article’s forward-looking statements are within the
meaning of the Private Securities Litigation Reform
Act of 1995. While Bio-Matrix Scientific Group,
Inc. believes its research, performance, forecasting
and assumptions are reasonable, there are some
external factors that are hard to predict and influenced
by economic and other conditions that can
influence the outcome of performance. Princeton
Research, Inc. has accepted compensation from
Bio-Matrix Scientific Group, Inc. in the form of
25,000 shares of restricted shares for investor relations.
• Educate the medical professionals
of selected specialties in the technology
services of Bio-Matrix.
• Build and maintain these professional
relationships as a resource.
• Acquire service customers through
• Utilize a sophisticated team of scientists
and medical professionals to
keep communications and relations
open with specialists for needs
analysis and further development.
• Visibility through participation in professional
association meetings and
conferences, business media releases,
and community participation.